MXPA03010336A - Analogos de adenosina para el tratamiento del sindrome de resistencia a la insulina y diabetes. - Google Patents

Analogos de adenosina para el tratamiento del sindrome de resistencia a la insulina y diabetes.

Info

Publication number
MXPA03010336A
MXPA03010336A MXPA03010336A MXPA03010336A MXPA03010336A MX PA03010336 A MXPA03010336 A MX PA03010336A MX PA03010336 A MXPA03010336 A MX PA03010336A MX PA03010336 A MXPA03010336 A MX PA03010336A MX PA03010336 A MXPA03010336 A MX PA03010336A
Authority
MX
Mexico
Prior art keywords
alkyl
hydrogen
diabetes
treatment
insulin resistance
Prior art date
Application number
MXPA03010336A
Other languages
English (en)
Inventor
Michael R Myers
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA03010336A publication Critical patent/MXPA03010336A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invencion se refiere al uso de compuestos de adenosina descritos por la formula I (Ver formula) y ciertos derivados de los mismos para la produccion de un farmaco para el tratamiento del sindrome de resistencia a la insulina y diabetes. En la formula (Ver formula) R, es hidrogeno, alquilo, alilo, 2-metalilo, 2-butenilo o cicloalquilo; (Ver formula) E es 0 o bien S; Y es por ejemplo hidrogeno, alquilo, aralquilo, arilo; n y p son, independientemente, 0, 1, 2 o 3, a condicion que n + p sea por lo menos 1; T es por ejemplo hidrogeno, alquilo, acilo, tioacilo, halo, carbonilo; R1, R2 y R3 son, independientemente, H, alquilo o cicloalquilo; A es hidrogeno, alquilo, hidroxialquilo, alcoxialquilo, o OR'; B es hidrogeno, alquilo, hidroxialquilo, alcoxialquilo, o bien OR"; R' y R" son, por ejemplo independientemente hidrogeno, alquilo, aralquilo o carbamoilo.
MXPA03010336A 2001-05-14 2002-05-14 Analogos de adenosina para el tratamiento del sindrome de resistencia a la insulina y diabetes. MXPA03010336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111651A EP1258247A1 (en) 2001-05-14 2001-05-14 Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
PCT/EP2002/005301 WO2002092093A1 (en) 2001-05-14 2002-05-14 Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes

Publications (1)

Publication Number Publication Date
MXPA03010336A true MXPA03010336A (es) 2004-03-16

Family

ID=8177414

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010336A MXPA03010336A (es) 2001-05-14 2002-05-14 Analogos de adenosina para el tratamiento del sindrome de resistencia a la insulina y diabetes.

Country Status (23)

Country Link
US (1) US20030176390A1 (es)
EP (2) EP1258247A1 (es)
JP (1) JP2004533448A (es)
KR (1) KR20040002962A (es)
CN (1) CN1518450A (es)
BG (1) BG108356A (es)
BR (1) BR0209650A (es)
CA (1) CA2447408A1 (es)
CO (1) CO5540288A2 (es)
CZ (1) CZ20033079A3 (es)
EA (1) EA007253B1 (es)
EE (1) EE200300551A (es)
HR (1) HRP20030928A2 (es)
HU (1) HUP0400464A3 (es)
IL (1) IL158794A0 (es)
MX (1) MXPA03010336A (es)
NO (1) NO20035056D0 (es)
NZ (1) NZ529390A (es)
PL (1) PL364573A1 (es)
SK (1) SK14052003A3 (es)
WO (1) WO2002092093A1 (es)
YU (1) YU90203A (es)
ZA (1) ZA200308777B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
CA2669108A1 (en) * 2006-11-10 2008-05-15 Novartis Ag Cyclopentene diol monoacetate derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
US5055569A (en) * 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
US6376472B1 (en) * 1996-07-08 2002-04-23 Aventis Pharmaceuticals, Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives

Also Published As

Publication number Publication date
WO2002092093A1 (en) 2002-11-21
KR20040002962A (ko) 2004-01-07
CN1518450A (zh) 2004-08-04
EE200300551A (et) 2004-02-16
BG108356A (bg) 2004-12-30
US20030176390A1 (en) 2003-09-18
JP2004533448A (ja) 2004-11-04
IL158794A0 (en) 2004-05-12
EP1258247A1 (en) 2002-11-20
NO20035056D0 (no) 2003-11-13
EA007253B1 (ru) 2006-08-25
CO5540288A2 (es) 2005-07-29
ZA200308777B (en) 2006-04-26
CZ20033079A3 (cs) 2004-08-18
PL364573A1 (en) 2004-12-13
BR0209650A (pt) 2004-07-13
CA2447408A1 (en) 2002-11-21
SK14052003A3 (sk) 2004-07-07
EA200301231A1 (ru) 2004-04-29
HUP0400464A3 (en) 2007-03-28
HRP20030928A2 (en) 2005-10-31
HUP0400464A2 (hu) 2004-07-28
NZ529390A (en) 2006-06-30
YU90203A (sh) 2006-08-17
EP1404338A1 (en) 2004-04-07

Similar Documents

Publication Publication Date Title
YU90203A (sh) Upotreba adenozina i analoga za izradu lekova za tretman sindroma rezistentnosti na insulin i dijabetesa
DE69531502D1 (de) Monoamid, diamid, thiol enthaltende metall-chelatierende verbindungen
ZA9290B (en) Phenylimidazolidines,process for their preparation,their use as medicaments and pharmaceutical compositions containing them
HU9301585D0 (en) Methods for producing phenyl-imidazolydine derivatives as well as medical preparatives containing said compounds
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
EE02995B1 (et) 1,3-oksatiolaannukleosiidi analoogide kasutamine hepatiit B ravimpreparaatide valmistamiseks
DE60019904D1 (de) Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
HUP0004531A2 (hu) VLA-4 által mediált leukocita adhéziót gátló 4-aminofenilalanin-vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk
DE69416306D1 (de) Sphingoglycolipid und verwendung davon
YU77701A (sh) 3-α-HIDROKSI-3Гџ-METOKSIMETIL-21-HETEROCIKLIČNO SUPSTITUISANI STEROIDI SA ANESTETIČKIM DEJSTVOM
HUP0102187A2 (hu) Azolo-triazinok és -pirimidinek, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
DK1473294T3 (da) Substituerede1,3-oxathiolaner med antivirale egenskaber
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
MX9700928A (es) Derivado de triazian y medicina que lo contiene.
ATE37869T1 (de) Benzoylharnstoffderivate und diese verbindungen enthaltende pestizide kompositionen.
GR3034023T3 (en) Phenyl carboxamide-isoxazole-derivatives and salts, process for their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them.
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
ATE28862T1 (de) Aktive kompositionen gegen motten, weisse fliegen und holzwuermer, pharmazeutische kompositionen und benzoylharnstoffderivaten.
TW200420567A (en) Quinazoline derivatives
TW259785B (en) Chemical compounds
HUP0303512A2 (hu) Biuretánszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE143955T1 (de) Substituierte piperazine, ihre verfahrensherstellung und die enthaltenen pharmazeutischen zusammenfassungen
RU2003130062A (ru) Бициклические производные гуанидина и их терапевтическое использование
HUP0000934A1 (hu) 4-{2-[N-(3-Fenoxi-2-hidroxi)-propil-amino]-etil}-anilid-származékok és az ezeket tartalmazó gyógyászati készítmények
HUT56488A (en) Stabilizer for compositions comprising 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide, stabilizing method and stabilized medicine

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SURFACE SPECIALTIES, S.A.

FA Abandonment or withdrawal